Exact Mass: 410.24906680000004
Exact Mass Matches: 410.24906680000004
Found 500 metabolites which its exact mass value is equals to given mass value 410.24906680000004,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Forskolin
Forskolin is a labdane diterpenoid isolated from the Indian Coleus plant. It has a role as a plant metabolite, an anti-HIV agent, a protein kinase A agonist, an adenylate cyclase agonist, an antihypertensive agent and a platelet aggregation inhibitor. It is a labdane diterpenoid, an acetate ester, an organic heterotricyclic compound, a triol, a cyclic ketone and a tertiary alpha-hydroxy ketone. Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant Coleus forskohlii. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. Forskolin is a natural product found in Plectranthus, Plectranthus barbatus, and Apis cerana with data available. Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant Coleus forskohlii. Has antihypertensive, positive ionotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. Potent activator of the adenylate cyclase system and the biosynthesis of cyclic AMP. From the plant Coleus forskohlii. Has antihypertensive, positive inotropic, platelet aggregation inhibitory, and smooth muscle relaxant activities; also lowers intraocular pressure and promotes release of hormones from the pituitary gland. D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D001993 - Bronchodilator Agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents A labdane diterpenoid isolated from the Indian Coleus plant. D020011 - Protective Agents > D002316 - Cardiotonic Agents C78274 - Agent Affecting Cardiovascular System D007155 - Immunologic Factors CONFIDENCE standard compound; INTERNAL_ID 408; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4753; ORIGINAL_PRECURSOR_SCAN_NO 4752 CONFIDENCE standard compound; INTERNAL_ID 408; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4747; ORIGINAL_PRECURSOR_SCAN_NO 4745 CONFIDENCE standard compound; INTERNAL_ID 408; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4785; ORIGINAL_PRECURSOR_SCAN_NO 4783 CONFIDENCE standard compound; INTERNAL_ID 408; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4767; ORIGINAL_PRECURSOR_SCAN_NO 4766 CONFIDENCE standard compound; INTERNAL_ID 408; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4849; ORIGINAL_PRECURSOR_SCAN_NO 4847 CONFIDENCE standard compound; INTERNAL_ID 408; DATASET 20200303_ENTACT_RP_MIX505; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4753; ORIGINAL_PRECURSOR_SCAN_NO 4748 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.202 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.164 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.188 [Raw Data] CB247_Forskolin_neg_30eV_000046.txt [Raw Data] CB247_Forskolin_neg_40eV_000046.txt [Raw Data] CB247_Forskolin_neg_10eV_000046.txt [Raw Data] CB247_Forskolin_neg_20eV_000046.txt Forskolin (Coleonol) is a potent adenylate cyclase activator with an IC50 of 41 nM and an EC50 of 0.5 μM for type I adenylyl cyclase[1]. Forskolin is also an inducer of intracellular cAMP formation[2]. Forskolin induces differentiation of various cell types and activates pregnane X receptor (PXR) and FXR[3]. Forskolin exerts a inotropic effect on the heart, and has platelet antiaggregatory and antihypertensive actions. Forskolin also induces autophagy[4][5].
LysoPA(16:0/0:0)
LysoPA(16:0/0:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293). Lysopa(16:0/0:0), also known as 1-palmitoyl lysophosphatidic acid or 1-hexadecanoyl-sn-glycero-3-phosphate, is a member of the class of compounds known as 1-acylglycerol-3-phosphates. 1-acylglycerol-3-phosphates are lysophosphatidic acids where the glycerol is esterified with a fatty acid at O-1 position. Thus, lysopa(16:0/0:0) is considered to be a glycerophosphate lipid molecule. Lysopa(16:0/0:0) is practically insoluble (in water) and a moderately acidic compound (based on its pKa). Lysopa(16:0/0:0) can be found in a number of food items such as alfalfa, soy bean, banana, and barley, which makes lysopa(16:0/0:0) a potential biomarker for the consumption of these food products. Lysopa(16:0/0:0) can be found primarily throughout all human tissues. Lysopa(16:0/0:0) exists in all living species, ranging from bacteria to humans. In humans, lysopa(16:0/0:0) is involved in several metabolic pathways, some of which include cardiolipin biosynthesis CL(16:0/18:1(11Z)/18:0/18:1(9Z)), cardiolipin biosynthesis CL(16:0/16:1(9Z)/16:1(9Z)/16:0), cardiolipin biosynthesis CL(16:0/20:4(5Z,8Z,11Z,14Z)/18:0/20:4(5Z,8Z,11Z,14Z)), and cardiolipin biosynthesis CL(16:0/18:1(11Z)/18:0/18:1(11Z)). Lysopa(16:0/0:0) is also involved in several metabolic disorders, some of which include de novo triacylglycerol biosynthesis TG(16:0/24:0/20:4(8Z,11Z,14Z,17Z)), de novo triacylglycerol biosynthesis TG(16:0/22:2(13Z,16Z)/22:0), de novo triacylglycerol biosynthesis TG(16:0/15:0/18:3(9Z,12Z,15Z)), and de novo triacylglycerol biosynthesis TG(16:0/15:0/24:0).
Norethindrone enanthate
D012102 - Reproductive Control Agents > D003270 - Contraceptive Agents Same as: D08285
5,8-Epoxy-5,8-dihydro-10'-apo-b,y-carotene-3,10'-diol
5,8-Epoxy-5,8-dihydro-10-apo-b,y-carotene-3,10-diol is found in citrus. 5,8-Epoxy-5,8-dihydro-10-apo-b,y-carotene-3,10-diol is isolated from Persea americana (avocado) and from Valencia orange juice. Isolated from Persea americana (avocado) and from Valencia orange juice. 5,8-Epoxy-5,8-dihydro-10-apo-b,y-carotene-3,10-diol is found in citrus and fruits.
5,6-Epoxy-5,6-dihydro-10'-apo-b,y-carotene-3,10'-diol
5,6-Epoxy-5,6-dihydro-10-apo-b,y-carotene-3,10-diol is found in pomes. 5,6-Epoxy-5,6-dihydro-10-apo-b,y-carotene-3,10-diol is isolated from the peel of the ripe Golden Delicious apple. 5,6-Epoxy-5,6-dihydro-10-apo-b,y-carotene-3,10-diol isa metabolite of
LysoPA(0:0/16:0)
LysoPA(0:0/16:0) is a lysophosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. Lysophosphatidic acids can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) or C-2 (sn-2) position. Fatty acids containing 16 and 18 carbons are the most common. Lysophosphatidic acid is the simplest possible glycerophospholipid. It is the biosynthetic precursor of phosphatidic acid. Although it is present at very low levels only in animal tissues, it is extremely important biologically, influencing many biochemical processes. In particular, lysophosphatidic acid is an intercellular lipid mediator with growth factor-like activities, and is rapidly produced and released from activated platelets to influence target cells. 1-Palmitoyl lysophosphatidic acid is the major component of lysophosphatidic acid (LPA) in plasma, and is in a reduced ratio in individuals with gynecological cancers (PMID 11585410). LPA is a pluripotent lipid mediator controlling growth, motility, and differentiation, that has a strong influence on the chemotaxis and ultrastructure of human neutrophils (PMID 7416233). In serum and plasma, LPA is mainly converted from lysophospholipids, whereas in platelets and some cancer cells it is converted from phosphatidic acid. In each pathway, at least two phospholipase activities are required: phospholipase A1 (PLA1)/PLA2 plus lysophospholipase D (lysoPLD) activities are involved in the first pathway and phospholipase D (PLD) plus PLA1/PLA2 activities are involved in the second pathway. (PMID 15271293).
2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl
2-[(4-Hydroxycyclohexyl)amino]-4-(3,6,6-trimethyl-4-oxo-5,7-dihydroindazol-1-yl)benzamide
C23H30N4O3 (410.23177899999996)
AT-533 is a potent Hsp90 and HSV inhibitor. AT-533 suppresses tumor growth and angiogenesis by blocking the HIF-1α/VEGF/VEGFR-2 signaling pathway. AT-533 also inhibits the activation of the downstream pathways, including Akt/mTOR/p70S6K, Erk1/2 and FAK. AT-533 inhibits the tube formation, cell migration, and invasion of human umbilical vein endothelial cells (HUVECs)[1][2][3].
Forskolin
Vesatolimod
C22H30N6O2 (410.24301199999996)
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C308 - Immunotherapeutic Agent > C2139 - Immunostimulant C254 - Anti-Infective Agent > C281 - Antiviral Agent
Isoforskolin
Norethisterone enanthate
1,25-Dihydroxy-16-ene-23-yne-vitamin D3
MG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/0:0)
MG(20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/0:0)
MG(20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/0:0)
MG(20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0)
MG(0:0/20:4(6Z,8E,10E,14Z)-2OH(5S,12R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0)
MG(0:0/20:4(6E,8Z,11Z,13E)-2OH(5S,15S)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
MG(0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0)
MG(0:0/20:4(8Z,11Z,14Z,17Z)-2OH(5S,6R)/0:0) is an oxidized monoacyglycerol (MG). Oxidized monoacyglycerols are glycerolipids in which the fatty acyl chain has undergone oxidation. As all oxidized lipids, oxidized monoacyglycerols belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with other lipids, monoacyglycerols can be substituted by different fatty acids, with varying lengths, saturation and degrees of oxidation attached at the C-1, C-2 and C-3 positions. Lipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with lipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized lipids is continually in flux, owing to lipid degradation and the continuous lipid remodeling that occurs while these molecules are in membranes. Oxidized MGs can be synthesized via three different routes. In one route, the oxidized MG is synthetized de novo following the same mechanisms as for MGs but incorporating an oxidized acyl chain (PMID: 33329396). An alternative is the transacylation of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the MG backbone, mainly through the action of LOX (PMID: 33329396).
DG(2:0/18:2(10E,12Z)+=O(9)/0:0)
DG(2:0/18:2(10E,12Z)+=O(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:2(10E,12Z)+=O(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/2:0/0:0)
DG(18:2(10E,12Z)+=O(9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(10E,12Z)+=O(9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:2(10E,12Z)+=O(9))
DG(2:0/0:0/18:2(10E,12Z)+=O(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(10E,12Z)+=O(9)/0:0/2:0)
DG(18:2(10E,12Z)+=O(9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/18:2(9Z,11E)+=O(13)/0:0)
DG(2:0/18:2(9Z,11E)+=O(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:2(9Z,11E)+=O(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/2:0/0:0)
DG(18:2(9Z,11E)+=O(13)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:2(9Z,11E)+=O(13)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:2(9Z,11E)+=O(13))
DG(2:0/0:0/18:2(9Z,11E)+=O(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:2(9Z,11E)+=O(13)/0:0/2:0)
DG(18:2(9Z,11E)+=O(13)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/18:3(10,12,15)-OH(9)/0:0)
DG(2:0/18:3(10,12,15)-OH(9)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:3(10,12,15)-OH(9)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/2:0/0:0)
DG(18:3(10,12,15)-OH(9)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(10,12,15)-OH(9)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:3(10,12,15)-OH(9))
DG(2:0/0:0/18:3(10,12,15)-OH(9)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(10,12,15)-OH(9)/0:0/2:0)
DG(18:3(10,12,15)-OH(9)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(2:0/18:3(9,11,15)-OH(13)/0:0)
DG(2:0/18:3(9,11,15)-OH(13)/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(2:0/18:3(9,11,15)-OH(13)/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/2:0/0:0)
DG(18:3(9,11,15)-OH(13)/2:0/0:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. DG(18:3(9,11,15)-OH(13)/2:0/0:0) is also a substrate of diacylglycerol kinase. It is involved in the phospholipid metabolic pathway.
DG(2:0/0:0/18:3(9,11,15)-OH(13))
DG(2:0/0:0/18:3(9,11,15)-OH(13)) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
DG(18:3(9,11,15)-OH(13)/0:0/2:0)
DG(18:3(9,11,15)-OH(13)/0:0/2:0) belongs to the family of Diacylglycerols. These are glycerolipids lipids containing a common glycerol backbone to which at least one fatty acyl group is esterified. It is involved in the phospholipid metabolic pathway.
Sinensiaxanthin
Sinensiaxanthin is a member of the class of compounds known as sesterterpenoids. Sesterterpenoids are terpenes composed of five consecutive isoprene units. Sinensiaxanthin is practically insoluble (in water) and an extremely weak acidic compound (based on its pKa). Sinensiaxanthin can be found in apple and sweet orange, which makes sinensiaxanthin a potential biomarker for the consumption of these food products.
X2F6R0716P
Rhodojaponin II is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity[1]. Rhodojaponin II is a diterpenoid from the leaves of Rhododendron molle with anti-inflammatory activity[1].
Rhodojaponin V
5,6,10,16-Tetrahydroxy-2,3-epoxygrayanotoxan-14-yl acetate is a natural product found in Rhododendron japonicum with data available.
Coleonol B
Isoforskolin is a natural product found in Excoecaria cochinchinensis with data available.
(+)-Makassaric acid
A meroterpenoid isolated from the marine sponge Acanthodendrilla sp. It exhibits inhibitory activity against the enzyme mitogen-activated protein kinase-activated protein kinase 2 (EC 2.7.11.1).
6-(4,5-dihydroxy-2-hexenoyloxy)-5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl]-1-oxaspiro[2,5]octane
carisson-(alpha-xylopyranoside-2-O-acetate)|carisson-
methyl-13S,15-dihydroxy-14R-acetoxy-1(10)-ent-halimen-18-oate
17-acetoxy-1-methyl-19,20-dihydro-sarpagane-16-carboxylic acid methyl ester|17-O-Acetyl-19,20-dihydrovachalotine
1beta,1beta:21,23-diepoxy-7alpha-hydroxy-24,25,26,27-tetranor-apotirucalla-14,20,22-trien-3-one
methyl-2alpha-acetoxy-3alpha,9beta-dihydroxy-9-epi-labd-13(E)-en-15-oate
6alpha-({4-acetoxy}-7Z-coumaryloxy)eudesm-4(14)-ene
15-epi-leosibirone B|3alpha-acetoxy-7beta,15beta-dihydroxy-9alpha,13alpha;15,16-diepoxylabd-6-one
3-O-(3-acetoxy-2-hydroxy-2-methylbutyryl)cuauthemone
rhodomollein G,2a,3b,14b,16a-tetrahydroxyl-6b-acetoxy-5,9-epoxy grayanotoxane
(rel-3S,5S,8R,9R,10S,13S,15S,16R)-3-acetoxy-9,13; 15,16-diepoxy-15,16-dimethoxylabdane|vitextrifolin A
6beta-acetoxy-9,13-epoxy-1alpha,7beta,8alpha-trihydroxy-labd-14-ene-11-one|spirocoleonol B
(16S*)-(9alpha-16alpha),(15-16alpha)-diepoxy-13beta,14beta-dihydroxy-15alpha-ethoxylabdan-6beta(19)-olide|marrulibacetal
1-(2,4,6-trihydroxyphenyl)-5,8,11,14,17-eicosapentaen-1-one
9-oxo-3-O-(2-O-acetyl-beta-D-xylopyranosyl)-nerolidol
1-alpha-acetoxy-7beta,12beta,15alpha-trihydroxy-16alpha-hydroxymethyl-7,20-epoxy-ent-kaurane|taibaijaponicain C
2beta,3beta,5beta,6beta,16alpha-pentahydroxy-14-acetylgrayan-10(20)-ene|rhodomolin B
tilorone
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals D007155 - Immunologic Factors > D007369 - Interferon Inducers D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent D000893 - Anti-Inflammatory Agents D000970 - Antineoplastic Agents Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels[1][2][3][4][5].
2-(2-acetyloxy-12-hydroxytridecyl)-4,6-dihydroxybenzoic acid
Ala Ala His Ile
Ala Ala His Leu
Ala Ala Ile His
Ala Ala Leu His
Ala His Ala Ile
Ala His Ala Leu
Ala His Ile Ala
Ala His Leu Ala
Ala Ile Ala His
Ala Ile His Ala
Ala Leu Ala His
Ala Leu His Ala
Gly His Val Val
Gly Val His Val
Gly Val Val His
His Ala Ala Ile
His Ala Ala Leu
His Ala Ile Ala
His Ala Leu Ala
His Gly Val Val
His Ile Ala Ala
His Leu Ala Ala
His Val Gly Val
His Val Val Gly
Ile Ala Ala His
Ile Ala His Ala
Ile His Ala Ala
Leu Ala Ala His
Leu Ala His Ala
Leu His Ala Ala
Pro Pro Pro Thr
Pro Pro Thr Pro
Pro Pro Val Val
Pro Thr Pro Pro
Pro Val Pro Val
Pro Val Val Pro
Thr Pro Pro Pro
Val Gly His Val
Val Gly Val His
Val His Gly Val
Val His Val Gly
Val Pro Pro Val
Val Pro Val Pro
Val Val Gly His
Val Val His Gly
Val Val Pro Pro
2-eicosa-5Z,8Z,11Z,14Z,17Z-pentaenoylphloroglucinol
trans,trans-3,4,5-trifluorophenyl 4-pentylbicyclohexyl-4-carboxylate
Trimipramine maleate
D018377 - Neurotransmitter Agents > D014179 - Neurotransmitter Uptake Inhibitors > D018759 - Adrenergic Uptake Inhibitors C78272 - Agent Affecting Nervous System > C265 - Antidepressant Agent > C94727 - Tricyclic Antidepressant D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D000928 - Antidepressive Agents D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents D049990 - Membrane Transport Modulators Trimipramine maleate is a 5-HT receptor antagonist, with pKi binding values of 6.39, 8.10, 4.66 for 5-HT1C, 5-HT2 and 5-HT1A, respectively[1]. Trimipramine maleate is also a potent and selective inhibitor targeting human noradrenaline (hNAT), serotonin (hSERT) and organic cation transporters (hOCT1, hOCT2) with IC50 values of 4.99 μM, 2.11 μM, 3.72 μM, 8.00 μM, respectively[2]. Trimipramine maleate has vascular activity and anxiolytic efficacy[3].
methyl trimethyl-3-[(1-oxododecyl)amino]propylammonium sulphate
C19H42N2O5S (410.28142820000005)
1-(2-ethoxyethyl)-2-[[4-(4-pyrazol-1-ylbutyl)piperazin-1-yl]methyl]benzimidazole
7BETA-ACETOXY-1ALPHA,6BETA-DIHYDROXY-8,13-EPOXY-LABD-14-EN-11-ONE
1,1-Biphenyl, 4-[(trans,trans)-4-butyl[1,1-bicyclohexyl]-4-yl]-3,4-difluoro-
1-Ethoxy-2,3-difluoro-4-[[4-(trans-4-pentylcyclohexyl)phenyl]ethynyl]benzene
C27H32F2O (410.24210859999994)
trans-4-Pentylcyclohexanecarboxylic acid 2,3-dicyano-4-(pentyloxy)phenyl ester
(Z)-4-[3-(2-CHLORO-9H-THIOXANTHEN-9-YLIDENE)PROPYL]PIPERAZINE-1-ETHANOLDIHYDROCHLORIDE
(2R)-2-hydroxy-3-(phosphonooxy)propyl hexadecanoate
(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]hexanoic acid
(2S,3R)-2-[[(2S)-2-[[(2S)-2,6-diaminohexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoic acid
(2S)-6-amino-2-[[(2S,3R)-2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxybutanoyl]amino]hexanoic acid
2-(2-Acetoxy-12-hydroxytridecyl)-4,6-dihydroxybenz
GS-9620
C22H30N6O2 (410.24301199999996)
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents C308 - Immunotherapeutic Agent > C2139 - Immunostimulant C254 - Anti-Infective Agent > C281 - Antiviral Agent
[(2R)-2-(hexadecanoyloxy)-3-hydroxypropoxy]phosphonic acid
[(2S)-1-acetyloxy-3-hydroxypropan-2-yl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-2-acetyloxy-3-hydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2R)-3-acetyloxy-2-hydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-3-acetyloxy-2-hydroxypropyl] (10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoate
[(2S)-1-acetyloxy-3-hydroxypropan-2-yl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-2-acetyloxy-3-hydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2R)-3-acetyloxy-2-hydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[(2S)-3-acetyloxy-2-hydroxypropyl] (9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoate
[3-carboxy-2-[(3E,5E,11E)-14-carboxytetradeca-3,5,11-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(9E,11E,13E)-14-carboxytetradeca-9,11,13-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(3E,6E,9E)-14-carboxytetradeca-3,6,9-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(7E,10E,13E)-14-carboxytetradeca-7,10,13-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(4E,6E,8E)-14-carboxytetradeca-4,6,8-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(5E,8E,11E)-14-carboxytetradeca-5,8,11-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(2E,6E,10E)-14-carboxytetradeca-2,6,10-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(5E,7E,9E)-14-carboxytetradeca-5,7,9-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
[3-carboxy-2-[(3E,5E,7E)-14-carboxytetradeca-3,5,7-trienoyl]oxypropyl]-trimethylazanium
C22H36NO6+ (410.25424960000004)
7-Hexyl-3-methyl-8-(4-phenyl-1-piperazinyl)purine-2,6-dione
C22H30N6O2 (410.24301199999996)
N-arachidonoyltaurine(1-)
C22H36NO4S- (410.2364916000001)
A fatty acid-taurine conjugate obtained by deprotonation of the sulfonate group of N-arachidonoyltaurine; major species at pH 7.3.
15-epi-Leosibirone B, (rel)-
A natural product found in Leonurus sibiricus.
1-[(1-Tert-butyl-5-tetrazolyl)-thiophen-2-ylmethyl]-4-(2,3-dimethylphenyl)piperazine
1-[2-(1-Cyclohexenyl)ethyl]-5-[[4-(diethylamino)anilino]methylidene]-1,3-diazinane-2,4,6-trione
C23H30N4O3 (410.23177899999996)
N-[2-[4-(4-fluorophenyl)-1-piperazinyl]-2-(3-pyridinyl)ethyl]cyclohexanecarboxamide
C24H31FN4O (410.24817679999995)
5-tert-butyl-N-[2-(cyclopentylamino)-2-oxoethyl]-N-(2,5-dimethylphenyl)-3-methyl-2-furancarboxamide
benzoic acid [3-hydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl] ester
N-Benzyl-3-[(2S,5aS,8aR)-6-(1H-imidazol-2-ylmethyl)-1-methyl-5-oxodecahydropyrrolo[3,2-E][1,4]diazepin-2-yl]propanamide
C22H30N6O2 (410.24301199999996)
1,3-dihydroxypropan-2-yl (5Z,8Z,11Z,13E,15S)-15-hydroperoxyicosa-5,8,11,13-tetraenoate
(E)-3-(((quinolin-8-ylmethylene)amino)oxy)butyl undec-10-enoate
5-[3-(dimethylammonio)-2-methylpropyl]-10,11-dihydro-5H-dibenzo[b,f]azepinium (2Z)-but-2-enedioate
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(1S,3S,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-phenylethyl)acetamide
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-phenylethyl)acetamide
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide
(6S,7S,8R)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8S)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
2-[(1R,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-phenylethyl)acetamide
2-[(1S,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-(2-phenylethyl)acetamide
2-[(1S,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1R,3R,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1R)-1-phenylethyl]acetamide
2-[(1R,3S,4aS,9aR)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1S,3R,4aR,9aS)-6-(dimethylamino)-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
(6R,7R,8R)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7R,8S)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8R)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7S,8S)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6S,7R,8S)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
(6R,7S,8R)-4-[cyclohexyl(oxo)methyl]-8-(hydroxymethyl)-7-[4-(3-methoxyprop-1-ynyl)phenyl]-1,4-diazabicyclo[4.2.0]octan-2-one
3-[[(3R,5R,7S,8E,10E,12E)-3-amino-5-hydroxy-7-methoxyoctadeca-8,10,12-trienoyl]amino]propanoic acid
[2-(Butanoylamino)-3-hydroxynonyl] 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
(2-Acetamido-3-hydroxyundecyl) 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
[3-Hydroxy-2-(propanoylamino)decyl] 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
[3-Hydroxy-2-(pentanoylamino)octyl] 2-(trimethylazaniumyl)ethyl phosphate
C18H39N2O6P (410.25456040000006)
1-Palmitoylglycerol 3-phosphate
A monoacylglycerol phosphate having palmitoyl as the acyl group on O-1 and with the phosphate group on O-3.
Nigakihemiacetal A
A quassinoid that is picras-2-ene substituted by hydroxy groups at positions 11, 13 and 16, methoxy groups at positions 2 and 12 and an oxo group at position 1 (the 11alpha,12beta stereoisomer).
1-Palmitoyl-sn-glycerol 3-phosphate
A 1-acyl-sn-glycerol 3-phosphate having palmitoyl as the acyl group.
lysophosphatidic acid 16:0
A lysophosphatidic acid in which the acyl group (position not specified) contains 16 carbons and no double bonds.
TG(20:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved